Literature DB >> 15624204

Diminished expression of CD19 in B-cell lymphomas.

Wei Yang1, Neeta Agrawal, Jigar Patel, Alison Edinger, Ebenezer Osei, Dawn Thut, Jennifer Powers, Howard Meyerson.   

Abstract

BACKGROUND: CD19 is expressed on most B-cell lymphomas; however, the frequency and types of B-cell lymphomas with low-level expression of CD19 are not well characterized.
METHODS: We reviewed flow cytometric histograms specifically for decreased CD19 expression on 349 cases analyzed by the Flow Cytometry Laboratory at University Hospitals of Cleveland (Cleveland, Ohio). Results of flow cytometry were correlated with the morphologic diagnosis.
RESULTS: Of the cases reviewed, 125 (36%) showed a visible decrease in CD19 expression compared with normal B lymphocytes. Decreased CD19 expression was noted in 79% of follicular lymphomas (27 of 34), 36% of small lymphocytic lymphomas/chronic lymphocytic leukemias (82 of 228), 31% of mantle cell lymphomas (4 of 13), 24% of diffuse large B-cell lymphomas (8 of 33), and 13% of marginal zone B-cell lymphomas/lymphoplasmacytoid lymphomas (4 of 30) and was not observed in any Burkitt lymphoma (0 of 5) or hairy cell leukemia (0 of 6). Decreased CD19 expression was significantly more frequent in follicular lymphomas than in other lymphoma subtypes (P < 0.001). No significant difference was observed in the frequency of decreased CD19 expression based on histologic grade of follicular lymphoma.
CONCLUSIONS: Diminished expression of CD19 expression occurs frequently in B-cell lymphomas, in particular follicular lymphoma, and may be helpful in identifying B-cell lymphoma cells in complex cell mixtures such as bone marrow specimens. (c) 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15624204     DOI: 10.1002/cyto.b.20030

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


  9 in total

1.  Molecular analysis of a CD19-negative diffuse large B-cell lymphoma.

Authors:  Lorric Delage; Delphine Manzoni; Charles Quinquenet; Juliette Fontaine; Alizée Maarek; Kaddour Chabane; Isabelle Mosnier; Sandrine Hayette; Evelyne Callet-Bauchu; Beatrice Grange; Adriana Plesa; Pierre Sujobert
Journal:  Haematologica       Date:  2018-12-13       Impact factor: 9.941

2.  CD48 on hematopoietic progenitors regulates stem cells and suppresses tumor formation.

Authors:  Nathan C Boles; Kuanyin K Lin; Georgi L Lukov; Teresa V Bowman; Megan T Baldridge; Margaret A Goodell
Journal:  Blood       Date:  2011-05-16       Impact factor: 22.113

Review 3.  Novel disease targets and management approaches for diffuse large B-cell lymphoma.

Authors:  Wyndham H Wilson; Francisco J Hernandez-Ilizaliturri; Kieron Dunleavy; Richard F Little; Owen A O'Connor
Journal:  Leuk Lymphoma       Date:  2010-08

4.  Identification of an Atypical Enzootic Bovine Leukosis in Japan by Using a Novel Classification of Bovine Leukemia Based on Immunophenotypic Analysis.

Authors:  Asami Nishimori; Satoru Konnai; Tomohiro Okagawa; Naoya Maekawa; Shinya Goto; Ryoyo Ikebuchi; Ayako Nakahara; Yuzumi Chiba; Masaho Ikeda; Shiro Murata; Kazuhiko Ohashi
Journal:  Clin Vaccine Immunol       Date:  2017-09-05

Review 5.  Engineered T cells: the promise and challenges of cancer immunotherapy.

Authors:  Andrew D Fesnak; Carl H June; Bruce L Levine
Journal:  Nat Rev Cancer       Date:  2016-08-23       Impact factor: 60.716

6.  Clinicopathologic significance of loss of CD19 expression in diffuse large B-cell lymphoma.

Authors:  Miho Kimura; Motoko Yamaguchi; Shigeo Nakamura; Hiroshi Imai; Satoshi Ueno; Shoko Ogawa; Kana Miyazaki; Kouji Oka; Toshiyuki Ohno; Kenkichi Kita; Tohru Kobayashi; Hiroshi Shiku
Journal:  Int J Hematol       Date:  2007-01       Impact factor: 2.490

7.  Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival.

Authors:  Nathalie A Johnson; Merrill Boyle; Ali Bashashati; Stephen Leach; Angela Brooks-Wilson; Laurie H Sehn; Mukesh Chhanabhai; Ryan R Brinkman; Joseph M Connors; Andrew P Weng; Randy D Gascoyne
Journal:  Blood       Date:  2008-11-24       Impact factor: 22.113

8.  Assessment of immunological changes in Epstein-Barr virus co-infection in Egyptian chronic HCV patients.

Authors:  Sahar Shoman; Mohamed Nabil; Ashraf Tabl; Hussam Ghanem; Sherif El Kafrawy
Journal:  Mem Inst Oswaldo Cruz       Date:  2014-08-22       Impact factor: 2.743

9.  CD19: a biomarker for B cell development, lymphoma diagnosis and therapy.

Authors:  Kemeng Wang; Guoqing Wei; Delong Liu
Journal:  Exp Hematol Oncol       Date:  2012-11-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.